Clinical trials: Seizure, Partial Onset
Epilepsy, Focal
A Study of Brivaracetam in Subjects With Partial Onset Seizures
This trial will evaluate the efficacy and safety of brivaracetam (at doses of 50 and 150 mg/day in twice a day administration) as add on therapy in subjects with focal epilepsy
- Trial name
- NCT00175929
- Testing
- Brivaracetam
- Where
- 56 sites in Belgium, Czechia and 7 more
- Volunteers
- 157 people
- Sponsor
- UCB Pharma
Partial Epilepsy
Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures
The primary objective of this study is to assess the pharmacokinetics of cenobamate (YKP3089) in pediatric subjects with partial-onset (focal) seizures following single and multiple-dosing.
- Trial name
- NCT04903314
- Testing
- Xcopri
- Where
- 13 sites in United States, Hungary and 1 more
- Volunteers
- 26 people
- Sponsor
- SK Life Science, Inc.
Epilepsy
Study in Pediatric Subjects With Epilepsy
This is an open-label study to evaluate the pharmacokinetics, safety and tolerability of ezogabine/retigabine in subjects aged 12 years to less than 18 years with uncontrolled partial onset seizures or Lennos-Gastaut syndrome.
- Trial name
- NCT01494584
- Testing
- ezogabine/retigabine
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- GlaxoSmithKline
Partial Epilepsy
Safety and Anticonvulsant Efficacy of Passiflora Incarnata Extract in Patients With Partial Epilepsy
The purpose of the Phase II clinical trial will be to see if a botanical extract from the plant Passiflora incarnata can improve seizure control and reduce anxiety in patients diagnosed with partial epilepsy.
- Trial name
- NCT00982787
- Testing
- Botanical extract from Passiflora incarnata
- Where
- United States
- Sponsor
- Oregon Health and Science University
Epilepsy, Seizures
A Study of Intravenous Perampanel in Japanese Participants With Epilepsy
The purpose of the study is to evaluate the safety and tolerability of perampanel administered as a 30-minute intravenous infusion after switching from oral tablets (8 to 12 milligrams per day [mg/day]) as an adjunctive therapy…
- Trial name
- NCT03754582
- Testing
- Perampanel
- Where
- 13 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Eisai Co., Ltd.
Epilepsy
A Study to Evaluate the Efficacy and Safety of Perampanel Monotherapy in Untreated Participants With Focal Onset Seizures With or Without Focal to Bilateral Tonic-clonic Seizures
The primary purpose of this study is to evaluate the efficacy of perampanel monotherapy measured by the seizure-free rate during the Maintenance Period (24 weeks) of the Treatment Phase in untreated participants with focal onset…
- Trial name
- NCT05533814
- Testing
- Perampanel
- Where
- 10 sites in South Korea
- Volunteers
- 125 people
- Sponsor
- Eisai Korea Inc.
Epilepsy
Eslicarbazepine Acetate as Add-On Treatment to One Baseline Antiepileptic Drug (ESLADOBA)
This is a multicenter, non-interventional, prospective study. The observation period comprises at least 6 months, from the initiation of ESL add-on therapy in adult patients with partial-onset epilepsy not sufficiently controlled…
- Trial name
- NCT01532726
- Testing
- ESL
- Where
- Portugal
- Volunteers
- 56 people
- Sponsor
- Bial - Portela C S.A.
Epilepsy, Partial-onset Seizures
Open-label Study to Evaluate the Safety and Tolerability of iv Lacosamide in Japanese Adults With Partial-onset Seizures
EP0024 is a Phase 3, multicenter, open-label study to evaluate the safety and tolerability of intravenous (iv) lacosamide (LCM).
- Trial name
- NCT02192814
- Testing
- Lacosamide (200 mg/20 mL)
- Where
- 5 sites in Japan
- Volunteers
- 9 people
- Sponsor
- UCB Japan Co. Ltd.
Epilepsy, Partial
Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures
This trial will evaluate the efficacy and safety of ucb 44212 as add on therapy in subjects with focal epilepsy.
- Trial name
- NCT00152451
- Testing
- Seletracetam (ucb 44212)
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- UCB S.A. - Pharma Sector
Epilepsy With Partial Onset Seizures With or Without Secondary Generalization, Psychoses
Epileptic Psychoses and Their Link With Ictal Emotions and Consciousness
Background : Psychiatric comorbidities are common in epilepsy, affecting 50 to 70% of patients, especially when the epilepsy is focal and drug-resistant.
- Conditions
- Epilepsy With Partial Onset Seizures With or Without Secondary Generalization, Psychoses, Epilepsy, Generalized
- Trial name
- ASPAIC (NCT06960811)
- Where
- France
- Volunteers
- 117 people
- Sponsor
- Central Hospital, Nancy, France
Partial Seizures (With or Without Secondary Generalized Seizures), Primary Generalized Tonic-clonic Seizures
Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adolescence Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures
The objective of this study is to identify the following in adolescent epilepsy participants with partial-onset seizures (with or without secondary generalized seizures) or primary generalized Tonic-clonic seizures who receive…
- Trial name
- FYC02T (NCT03059381)
- Testing
- Fycompa
- Where
- 2 sites in Japan
- Volunteers
- 519 people
- Sponsor
- Eisai Co., Ltd.
Epilepsy
Open Label Trial to Study the Long-term Safety and Efficacy of Seletracetam for the Treatment of Epilepsy
This is a safety and efficacy study of add-on therapy with seletracetam in epilepsy patients who have participated in a previous seletracetam study
- Trial name
- NCT00175851
- Testing
- Seletracetam (ucb 44212)
- Sponsor
- UCB Pharma
Focal Epilepsy With and Without Secondary Generalization
Real-world Clinical Response to Cenobamate Early add-on in France, Germany and Spain
Aim of the study is to better characterize the clinical profile of adjunctive cenobamate by collecting data from the current standard clinical practice in France, Germany, and Spain, to describe the real-world clinical response…
- Trial name
- NCT06716801
- Testing
- Cenobamate
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A
Partial Seizures
Evaluation of the Efficacy and Safety of Adjunctive Zonisamide vs Replacement With Zonisamide of the Last Added Antiepileptic Drug
An open-label, randomized, multi-centre, superiority study to assess that, in patients who respond to zonisamide added as third drug after failure of a two-drug combination therapy, the triple therapy is superior to the…
- Trial name
- NCT01630057
- Testing
- Adjunctive Zonisamide, Replacement with Zonisamide
- Where
- 19 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Eisai Inc.
Partial Epilepsy
A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
This is a multicenter, double-blind, randomized, placebo-controlled dose response study, with an 8-week prospective baseline and an 18 week double-blind treatment period (including a 6-week titration phase and 12 week maintenance…
- Trial name
- NCT01866111
- Testing
- YKP3089
- Where
- 67 sites in United States, Australia and 13 more
- Volunteers
- 437 people
- Sponsor
- SK Life Science, Inc.
Partial Seizures With Secondary Generalization, Focal Epilepsy With Secondary Generalization
A Pilot Study: Focused Ultrasound Thalamotomy for the Prevention of Secondary Generalization in Focal Onset Epilepsy
The purpose of this study is to assess the safety and feasibility of unilateral focused ultrasound thalamotomy in adults with focal onset epilepsy whose medicines are not working well.
- Trial name
- NCT03417297
- Testing
- High Intensity Focused Ultrasound
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of North Carolina, Chapel Hill
Epilepsy, Epilepsies, Partial
A Study of the Effectiveness and Safety of Topiramate Monotherapy in Patients With Recently Diagnosed Partial-Onset Seizure
The purposes of this study are (1) to compare the effectiveness of two doses of topiramate and (2) to assess the safety of topiramate alone in the treatment of pediatric and adult patients with recently diagnosed epilepsy…
- Conditions
- Epilepsy, Epilepsies, Partial, Seizures
- Trial name
- NCT00230698
- Testing
- topiramate
- Volunteers
- 451 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Focal Onset Seizure, Focal Onset Epilepsy
Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset Seizures
This Phase 2, prospective, interventional, active extension study was designed to evaluate the long-term safety and tolerability of NBI-921352 as adjunctive therapy in adult participants with focal onset seizures who completed 11…
- Trial name
- NCT05493293
- Testing
- NBI-921352
- Where
- 26 sites in Australia, Belgium and 5 more
- Volunteers
- 82 people
- Sponsor
- Neurocrine Biosciences
Seizures
Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures
The purpose of the study is to evaluate the effectiveness and safety of adjunctive RWJ-333369 at a dose of 200 or 400 mg/day in comparison with placebo in Korean and Japanese partial epilepsy patients who have poor seizure…
- Trial name
- NCT00697762
- Testing
- RWJ-333369
- Volunteers
- 56 people
- Sponsor
- SK Life Science, Inc.
Epilepsy, Partial
Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam
This trial will evaluate the efficacy and safety of UCB44212 as add-on therapy in subjects with focal epilepsy.
- Trial name
- NCT00152503
- Testing
- Seletracetam (UCB44212)
- Where
- 17 sites in United States, Canada
- Volunteers
- 59 people
- Sponsor
- UCB Pharma SA